-
Asia-Pacific Hereditary Angioedema (HAE) Therapeutics Markets 2018-2023: Marketed Products, Pipeline Analysis, Clinical Trial Analysis, Market Dynamics, Foreccasts and Deals
29 May 2018 10:24 GMT
… less invasive drug-delivery methods, and improved access to treatment. The difficulty … factors, such as average trial duration and trial size, influence the costs … Ruconest (Conestat alfa (Ruconest/Rhucin)) - Pharming Group NV
3 …
-
Conestat alfa by Pharming Group for Acute Ischemic Stroke: Likelihood of Approval
17 May 2024 03:08 GMT
… of the drug, company and its clinical trials play a fundamental … Conestat alfa (Ruconest/Rhucin) is the first recombinant analogue … for the treatment of rare diseases and unmet medical needs. The … found on GlobalData’s Pharmaceutical Intelligence Center.
-
Asia-Pacific Hereditary Angioedema (HAE) Therapeutics Markets 2016-2018 & 2023
30 May 2018 21:05 GMT
… less invasive drug-delivery methods, and improved access to treatment. The difficulty … factors, such as average trial duration and trial size, influence the costs … Ruconest (Conestat alfa (Ruconest/Rhucin)) - Pharming Group NV
3 …